Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $19.6667.

Several brokerages have recently weighed in on ORIC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 23rd. Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a report on Monday, December 8th. Oppenheimer upped their price objective on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Finally, HC Wainwright lifted their target price on Oric Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Friday, November 14th.

Oric Pharmaceuticals Trading Down 2.1%

Shares of ORIC opened at $8.25 on Friday. The stock has a market cap of $803.47 million, a P/E ratio of -4.77 and a beta of 1.32. The company has a 50-day moving average of $11.20 and a two-hundred day moving average of $10.93. Oric Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Thursday, November 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.08. As a group, analysts forecast that Oric Pharmaceuticals will post -2.17 EPS for the current fiscal year.

Insider Transactions at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 10,720 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at approximately $617,420.88. This represents a 13.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jacob Chacko sold 33,374 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $302,368.44. Following the completion of the sale, the chief executive officer directly owned 581,711 shares of the company’s stock, valued at $5,270,301.66. The trade was a 5.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 190,814 shares of company stock worth $2,171,318. 6.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vivo Capital LLC grew its position in Oric Pharmaceuticals by 50.3% in the 2nd quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock worth $31,735,000 after purchasing an additional 1,046,154 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Oric Pharmaceuticals by 3,646.1% during the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares during the period. Rafferty Asset Management LLC boosted its position in shares of Oric Pharmaceuticals by 50.7% during the first quarter. Rafferty Asset Management LLC now owns 77,424 shares of the company’s stock worth $432,000 after buying an additional 26,032 shares during the period. Alkeon Capital Management LLC grew its holdings in Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after buying an additional 500,000 shares in the last quarter. Finally, Resolute Capital Asset Partners LLC acquired a new stake in Oric Pharmaceuticals in the 2nd quarter valued at approximately $2,309,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.